SHR 1316Alternative Names: HTI-1088; HTI-1316
Latest Information Update: 28 Mar 2018
Price : *
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Programmed cell death-1 ligand-1inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer; Solid tumours
Most Recent Events
- 01 Mar 2018 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease) in China (IV) (NCT03474289)
- 26 Jun 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT03133247)
- 31 Dec 2015 Preclinical trials in Solid tumours in Australia (Parenteral)